What is Beam Therapeutics Inc?
, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.16B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 350,187 shares $1.2M | 0 |
| 3-6months | 8351,900 shares $12.2M | 0 |
| 6-9months | 8142,786 shares $3.7M | 0 |
| 9-12months | 12,906 shares $84k | 0 |